Table 2.
Comparison of laboratory indicators
| Indicators | Prostate carcinoma (n=126) | Benign prostatic hyperplasia (n=191) | t/Z | P |
|---|---|---|---|---|
| FBG (mmol/L) | 5.33 [4.88, 5.97] | 5.43 [4.66, 6.86] | -1.069 | 0.285 |
| HDL (mmol/L) | 1.13±0.30 | 1.22±0.32 | -2.451 | 0.015 |
| LDL (mmol/L) | 2.65±0.83 | 2.66±0.75 | -0.094 | 0.925 |
| VLDL (mmol/L) | 0.54 [0.38, 0.70] | 0.56 [0.36, 0.76] | -0.663 | 0.508 |
| TG (mmol/L) | 1.28 [0.89, 1.68] | 1.18 [0.68, 1.73] | 1.037 | 0.300 |
| PSA (ng/mL) | 23.32±9.85 | 14.03±4.70 | 9.871 | <0.001 |
| Neu (×109/L) | 5.18±1.99 | 4.49±1.40 | 3.383 | <0.001 |
| PLT (×109/L) | 194.37±43.48 | 194.24±43.55 | 0.026 | 0.979 |
| Mono (×109/L) | 0.53±0.15 | 0.45±0.14 | 4.609 | <0.001 |
| Lym (×109/L) | 1.31±0.27 | 1.48±0.23 | -5.552 | <0.001 |
| CRP (mg/L) | 2.90 [1.32, 4.39] | 2.12 [1.23, 3.18] | 3.254 | 0.001 |
| CK (U/L) | 84.78±33.27 | 80.74±28.92 | 1.114 | 0.266 |
| CK-MB (U/L) | 13.73±4.56 | 12.44±3.08 | 2.773 | 0.006 |
| ApoA1 (g/L) | 1.01±0.11 | 1.04±0.10 | -2.353 | 0.019 |
| NLR | 4.17±1.85 | 3.10±1.02 | 5.903 | <0.001 |
| MLR | 0.40 [0.32, 0.49] | 0.30 [0.22, 0.39] | 6.336 | <0.001 |
| PLR | 147.66 [119.23, 179.06] | 131.53 [108.25, 158.31] | 3.300 | <0.001 |
| SII | 729.21 [513.38, 1057.80] | 588.72 [435.48, 746.61] | 4.721 | <0.001 |
| SIRI | 2.04 [1.23, 2.89] | 1.35 [0.96, 1.82] | 6.162 | <0.001 |
| NAR | 5.16±2.09 | 4.32±1.34 | 4.020 | <0.001 |
Note: FBG, fasting blood glucose; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very low-density lipoprotein; TG, triglycerides; PSA, prostate-specific antigen; Neu, neutrophil count; Lym, lymphocyte count; Mono, monocyte count; PLT, platelet count; CRP, C-reactive protein; CK, creatine kinase; CKMB, creatine kinase-MB; ApoA1, apolipoprotein A1; NLR, neutrophil-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; SII, systemic immune inflammation index; SIRI, system inflammation response index; NAR, neutrophil-albumin ratio.